Log In
Print
BCIQ
Print
Print this Print this
 

Pralia, Prolia, Ranmark, Xgeva, denosumab (AMG 162)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb targeting receptor activator of NF-kappa B ligand (RANKL; TNFSF11)
Molecular Target Receptor activator of NF-kappa B ligand (RANKL) (TNFSF11)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$120.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today